Cargando…
P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431363/ http://dx.doi.org/10.1097/01.HS9.0000971156.02746.02 |
| _version_ | 1785091182702886912 |
|---|---|
| author | Johnson, Nathalie Lavie, David Borchmann, Peter Gregory, Gareth Herrera, Alex F. Minuk, Leonard Vucinic, Vladan Armand, Philippe Avigdor, Abraham Gasiorowski, Robin Herishanu, Yair Keane, Colm Kuruvilla, John Marceau West, Rachel Pillai, Pallavi Marinello, Patricia Timmerman, John |
| author_facet | Johnson, Nathalie Lavie, David Borchmann, Peter Gregory, Gareth Herrera, Alex F. Minuk, Leonard Vucinic, Vladan Armand, Philippe Avigdor, Abraham Gasiorowski, Robin Herishanu, Yair Keane, Colm Kuruvilla, John Marceau West, Rachel Pillai, Pallavi Marinello, Patricia Timmerman, John |
| author_sort | Johnson, Nathalie |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431363 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104313632023-08-17 P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA Johnson, Nathalie Lavie, David Borchmann, Peter Gregory, Gareth Herrera, Alex F. Minuk, Leonard Vucinic, Vladan Armand, Philippe Avigdor, Abraham Gasiorowski, Robin Herishanu, Yair Keane, Colm Kuruvilla, John Marceau West, Rachel Pillai, Pallavi Marinello, Patricia Timmerman, John Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431363/ http://dx.doi.org/10.1097/01.HS9.0000971156.02746.02 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Johnson, Nathalie Lavie, David Borchmann, Peter Gregory, Gareth Herrera, Alex F. Minuk, Leonard Vucinic, Vladan Armand, Philippe Avigdor, Abraham Gasiorowski, Robin Herishanu, Yair Keane, Colm Kuruvilla, John Marceau West, Rachel Pillai, Pallavi Marinello, Patricia Timmerman, John P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title | P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_full | P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_fullStr | P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_full_unstemmed | P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_short | P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_sort | p1065: updated results from an open-label phase 1/2 study of favezelimab in combination with pembrolizumab in patients with anti–pd-1–naive relapsed or refractory classical hodgkin lymphoma |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431363/ http://dx.doi.org/10.1097/01.HS9.0000971156.02746.02 |
| work_keys_str_mv | AT johnsonnathalie p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT laviedavid p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT borchmannpeter p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT gregorygareth p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT herreraalexf p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT minukleonard p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT vucinicvladan p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT armandphilippe p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT avigdorabraham p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT gasiorowskirobin p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT herishanuyair p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT keanecolm p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT kuruvillajohn p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT marceauwestrachel p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT pillaipallavi p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT marinellopatricia p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT timmermanjohn p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma |